164 related articles for article (PubMed ID: 37072350)
21. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
22. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
23. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
24. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
25. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Zurko J; Ramdial J; Shadman M; Ahmed S; Szabo A; Iovino L; Tomas AA; Sauter C; Perales MA; Shah NN; Acharya UH; Jacobson C; Soiffer RJ; Wang T; Komanduri KV; Jaglowski S; Kittai AS; Denlinger N; Iqbal M; Kharfan-Dabaja MA; Ayala E; Chavez J; Jain M; Locke FL; Samara Y; Budde LE; Mei MG; Pia AD; Feldman T; Ahmed N; Jacobs R; Ghosh N; Dholaria B; Oluwole OO; Hess B; Hassan A; Kenkre VP; Reagan P; Awan F; Nieto Y; Hamadani M; Herrera AF
Haematologica; 2023 Jan; 108(1):98-109. PubMed ID: 35833303
[TBL] [Abstract][Full Text] [Related]
27. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Beyar Katz O; Perry C; Grisariu-Greenzaid S; Yehudai-Ofir D; Luttwak E; Avni B; Zuckerman T; Sdayoor I; Stepensky P; Ringelstein-Harlev S; Bar-On Y; Libster D; Sharvit L; Amit O; Greenbaum U; Gold R; Herishanu Y; Benyamini N; Avivi I; Ram R
Eur J Haematol; 2023 Jul; 111(1):63-71. PubMed ID: 36964939
[TBL] [Abstract][Full Text] [Related]
28. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K; Wang Y; Hansen DK; Iacoboni G; Bachy E; Bansal R; Penack O; Müller F; Bethge W; Munoz J; Mohty R; Bücklein VL; Barba P; Locke FL; Lin Y; Jain MD; Subklewe M
Blood Adv; 2024 Apr; 8(8):1857-1868. PubMed ID: 38181508
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
30. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
[TBL] [Abstract][Full Text] [Related]
31. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
33. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
34. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.
Molina JC; Steinberg SM; Yates B; Lee DW; Little L; Mackall CL; Shalabi H; Shah NN
Transplant Cell Ther; 2022 Jan; 28(1):31.e1-31.e9. PubMed ID: 34687939
[TBL] [Abstract][Full Text] [Related]
35. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
36. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia.
Tan Y; Shan L; Zhao L; Deng B; Ling Z; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Tian Z; Zhang Y; Zhang J; Chang AH; Feng X; Pan J
J Hematol Oncol; 2023 Apr; 16(1):34. PubMed ID: 37020231
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
40. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience.
Beyar-Katz O; Perry C; On YB; Amit O; Gutwein O; Wolach O; Kedar R; Pikovsky O; Avivi I; Gold R; Ben-Ezra J; Shasha D; Ami RB; Ram R
Ann Hematol; 2022 Aug; 101(8):1769-1776. PubMed ID: 35731278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
